AbbVie (MEX:ABBV) Cyclically Adjusted PS Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ABBV AbbVie Inc MEX:ABBV
67 GF Score
Price MXN4,259.00
GF Value MXN3,711.12
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie  (MEX:ABBV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AbbVie Cyclically Adjusted PS Ratio Related Terms


AbbVie Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted PS Ratio Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.55 6.79 5.93 6.25 7.43

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.23 7.61 7.43 6.87 0.00

MEX:ABBV vs MRK, JNJ, AMGN: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.


MEX:ABBV
67GF Score
AbbVie Inc MEX:ABBV
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=167.396/333.9520*333.9520
=167.396

Current CPI (Jun. 2026) = 333.9520.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 75.833 241.428 104.895
201612 86.223 241.432 119.265
201703 76.796 243.801 105.193
201706 78.450 244.955 106.952
201709 79.192 246.819 107.149
201712 94.639 246.524 128.202
201803 90.314 249.554 120.858
201806 103.472 251.989 137.128
201809 101.686 252.439 134.521
201812 108.640 251.233 144.410
201903 102.392 254.202 134.515
201906 106.853 256.143 139.312
201909 112.874 256.759 146.809
201912 110.395 256.974 143.464
202003 136.185 258.115 176.198
202006 146.103 257.797 189.263
202009 160.664 260.280 206.140
202012 154.780 260.474 198.442
202103 149.824 264.877 188.895
202106 156.457 271.696 192.307
202109 165.954 274.310 202.037
202112 171.557 278.802 205.493
202203 151.606 287.504 176.099
202206 165.192 296.311 186.177
202209 167.761 296.808 188.755
202212 165.524 296.797 186.245
202303 124.074 301.836 137.276
202306 134.218 305.109 146.906
202309 136.981 307.789 148.625
202312 136.683 306.746 148.806
202403 115.228 312.332 123.204
202406 149.602 314.175 159.019
202409 160.678 315.301 170.183
202412 177.344 315.605 187.654
202503 154.048 319.799 160.866
202506 163.977 322.561 169.768
202509 163.317 324.800 167.919
202512 168.479 324.054 173.625
202603 152.495 330.213 154.222
202606 167.396 333.952 167.396

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,259.00 is trading 14.8% above its estimated GF Value™ of MXN3,711.12. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: MXN3,711.12 vs. price of MXN4,259.00 (14.8% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
67GF Score

Get the complete analysis for MEX:ABBV

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,259.00
Price
MXN3,711.12
GF Value